A Study of DPC 817 in HIV-Infected Males

This study has been completed.
Sponsor:
Information provided by:
Pharmasset
ClinicalTrials.gov Identifier:
NCT00040274
First received: June 24, 2002
Last updated: July 18, 2005
Last verified: July 2005

June 24, 2002
July 18, 2005
Not Provided
Not Provided
Not Provided
Not Provided
Complete list of historical versions of study NCT00040274 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
A Study of DPC 817 in HIV-Infected Males
A Placebo-Controlled, Dose-Escalation Study in HIV-1 Infected Subjects to Characterize the Safety, Tolerability, and Pharmacokinetics of Single Oral Doses of DPC 817

The purpose of this study is to evaluate DPC 817. The safety, dosages, and how the body responds to the drug will be studied.

The study will consist of two parts. Patients in Part A will receive a single dose of DPC 817 on two separate occasions and a placebo (a solution or tablet without the drug) on one occasion. Patients in Part B will receive two separate doses of DPC 817. Patients will be admitted to the clinical study unit the day before dosing (Day -1) and remain there for at least 48 hours after taking the study drug. Patients will return to the clinical study unit on Day 8 and Day 28 following the dose in the last treatment period. During the study there will be medical and medication histories taken, physical examinations, vital sign measurements, and routine clinical laboratory tests.

Interventional
Phase 1
Allocation: Randomized
Endpoint Classification: Pharmacokinetics Study
Intervention Model: Crossover Assignment
Masking: Double-Blind
Primary Purpose: Treatment
HIV Infections
Drug: DPC 817
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
30
Not Provided
Not Provided

Inclusion Criteria

Patients may be eligible for this study if they:

  • Are HIV positive
  • Are male and are between 18 years of age (or the legal age of consent, whichever is older) and 55 years of age
  • Are female and are between 18 years of age (or the legal age of consent, whichever is older) and 55 years of age and are not able to have children (females may participate in Part B only)
  • Have no clinically significant findings on physical examination or clinical laboratory evaluations
  • Have a CD4-lymphocyte count of 50 or more cells/mm3
  • Are able and willing to comply with the requirements of this study

Exclusion Criteria

Patients will not be eligible for this study if they:

  • Have an opportunistic infection characteristic of AIDS
  • Are receiving any approved or experimental HIV drugs. Any previous anti-HIV treatment must be stopped at least 4 weeks before the first dose of study medication
  • Are pregnant or breast-feeding
  • Are enrolled in other experimental drug studies or have recieved other experimental drugs within 30 days before the first dose of study drug
  • Have any disease that causes a problem with absorption of drugs
  • Have active hepatitis
  • Have a history of pancreatitis or peripheral neuropathy
  • Have received radiation therapy or chemotherapy within 30 days before the first dose of study drug
  • Have received treatment with drugs that affect the immune system within 30 days before the first dose of study drug or have received an HIV immunotherapeutic vaccine
  • Have taken prescription or over-the-counter products within 14 days of the first dose of study drug unless approved by the doctor
  • Are unable to comply with the dosing schedule and study procedures
Both
18 Years to 55 Years
No
Contact information is only displayed when the study is recruiting subjects
United States,   Germany
 
NCT00040274
DPC 817-201
Not Provided
Not Provided
Pharmasset
Not Provided
Not Provided
Pharmasset
July 2005

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP